 Cystic Fibrosis
"Cystic Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Descriptor ID |
D003550
|
| MeSH Number(s) |
C06.689.202 C08.381.187 C16.320.190 C16.614.213
|
| Concept/Terms |
Pancreatic Cystic Fibrosis- Pancreatic Cystic Fibrosis
- Cystic Fibrosis, Pancreatic
- Fibrocystic Disease of Pancreas
- Pancreas Fibrocystic Disease
- Pancreas Fibrocystic Diseases
- Cystic Fibrosis of Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis".
This graph shows the total number of publications written about "Cystic Fibrosis" by people in this website by year, and whether "Cystic Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1995 | 2 | 1 | 3 | | 1996 | 4 | 1 | 5 | | 1997 | 3 | 1 | 4 | | 1998 | 4 | 1 | 5 | | 1999 | 3 | 1 | 4 | | 2000 | 4 | 0 | 4 | | 2001 | 3 | 2 | 5 | | 2002 | 10 | 0 | 10 | | 2003 | 9 | 0 | 9 | | 2004 | 13 | 0 | 13 | | 2005 | 16 | 4 | 20 | | 2006 | 12 | 3 | 15 | | 2007 | 20 | 1 | 21 | | 2008 | 13 | 3 | 16 | | 2009 | 19 | 1 | 20 | | 2010 | 20 | 3 | 23 | | 2011 | 16 | 1 | 17 | | 2012 | 20 | 1 | 21 | | 2013 | 3 | 2 | 5 | | 2014 | 22 | 2 | 24 | | 2015 | 26 | 0 | 26 | | 2016 | 29 | 1 | 30 | | 2017 | 23 | 1 | 24 | | 2018 | 29 | 4 | 33 | | 2019 | 35 | 1 | 36 | | 2020 | 39 | 1 | 40 | | 2021 | 49 | 2 | 51 | | 2022 | 51 | 0 | 51 | | 2023 | 54 | 0 | 54 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis" by people in Profiles.
-
Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, Tian S, Mall MA. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. Am J Respir Crit Care Med. 2024 02 01; 209(3):299-306.
-
Miller JE, Taylor-Cousar JL, Humphries SM, Khatiwada A, Chen H, Wilson A, Vladar EK, Lynch DA, Li DA, Beswick DM. Chronic rhinosinusitis and olfaction after highly effective modulator therapy: The role of individual sinus inflammation. Int Forum Allergy Rhinol. 2024 May; 14(5):986-989.
-
Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Jun; 14(6):1079-1087.
-
Gross JE, Caceres S, Poch K, Epperson LE, Hasan NA, Jia F, Calado Nogueira de Moura V, Strand M, Lipner EM, Honda JR, Strong M, Davidson RM, Daley CL, Nick JA. Prospective healthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (pHALT NTM) study: Rationale and study design. PLoS One. 2023; 18(12):e0291910.
-
Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Rowe SM, Selvadurai H, Taylor-Cousar JL, Withers NJ, Ahluwalia N, Moskowitz SM, Prieto-Centurion V, Tan YV, Tian S, Weinstock T, Xuan F, Zhang Y, Ramsey B, Griese M. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J. 2023 12; 62(6).
-
Yellepeddi VK, Lindley B, Radetich E, Kumar S, Bhakta Z, Leclair L, Parrot M, Young DC. Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis. Antimicrob Agents Chemother. 2024 Jan 10; 68(1):e0099223.
-
Sanders DB, Bartz TM, Zemanick ET, Hoppe JE, Hinckley Stukovsky KD, Cogen JD, Bendy L, McNamara S, Enright E, Kime NA, Kronmal RA, Edwards TC, Morgan WJ, Rosenfeld M. A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies. Ann Am Thorac Soc. 2023 12; 20(12):1769-1776.
-
Kasperbauer S, Thomson R. Things They Are a Changing in the Field of Nontuberculous Mycobacteria. Clin Chest Med. 2023 12; 44(4):xiii-xiv.
-
Patil R, Magaret AS, Jain R, Taylor-Cousar J, Hughan KS, Kazmerski TM. Factors associated with pubertal growth outcomes in cystic fibrosis: Early Growth and Puberty in CF. J Cyst Fibros. 2024 May; 23(3):538-544.
-
Han EJ, Beswick DM, Eshaghian PH, Turner GA, Lee JT, Li DA, Wang MB, Taylor-Cousar JL, Suh JD. Decreases in Rhinology Care Utilization by People with Cystic Fibrosis on Highly Effective Modulator Therapy. Ann Otol Rhinol Laryngol. 2024 Mar; 133(3):340-344.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|